<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Etanercept (including biosimilars available in Canada): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Etanercept (including biosimilars available in Canada): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Etanercept (including biosimilars available in Canada): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12442" href="/d/html/12442.html" rel="external">see "Etanercept (including biosimilars available in Canada): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13284" href="/d/html/13284.html" rel="external">see "Etanercept (including biosimilars available in Canada): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F6655343"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious infections:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients treated with etanercept are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>
<p style="text-indent:-2em;margin-left:2em;">Etanercept should be discontinued if a patient develops a serious infection or sepsis.</p>
<p style="text-indent:-2em;margin-left:2em;">Reported infections include:</p>
<p style="text-indent:-2em;margin-left:6em;">Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before etanercept use and during therapy. Initiate treatment for latent infection prior to etanercept use.</p>
<p style="text-indent:-2em;margin-left:6em;">Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.</p>
<p style="text-indent:-2em;margin-left:6em;">Bacterial, viral, and other infections caused by opportunistic pathogens, including Legionella and Listeria.</p>
<p style="text-indent:-2em;margin-left:2em;">The risks and benefits of treatment with etanercept should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor patients closely for the development of signs and symptoms of infection during and after treatment with etanercept, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancies:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor blockers, including etanercept.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F167887"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Enbrel;</li>
<li>Enbrel Mini;</li>
<li>Enbrel SureClick</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866801"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Brenzys;</li>
<li>Enbrel;</li>
<li>Erelzi</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F167912"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antirheumatic, Disease Modifying;</li>
<li>
                        Tumor Necrosis Factor (TNF) Blocking Agent</li></ul></div>
<div class="block doa drugH1Div" id="F167891"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note</b>
<b>: </b>In Canada, Brenzys and Erelzi are approved as biosimilars to Enbrel (etanercept).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fff9249-5dc6-46cd-8b57-b9c24cf7d812">Ankylosing spondylitis or nonradiographic axial spondyloarthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ankylosing spondylitis or nonradiographic axial spondyloarthritis (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Patients with an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31436026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31436026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Once-weekly dosing:</i>
<b>SUBQ:</b> 50 mg once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24891317','lexi-content-ref-26269397','lexi-content-ref-16968715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24891317','lexi-content-ref-26269397','lexi-content-ref-16968715'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Twice-weekly dosing</i>: <b>SUBQ: </b>25 mg twice weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15345498','lexi-content-ref-14613288','lexi-content-ref-Yu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15345498','lexi-content-ref-14613288','lexi-content-ref-Yu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee83bdbc-6f57-438d-9ad5-ce26b1ad18ef">Graft-versus-host disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease (treatment) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute graft-vs-host disease, treatment:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial treatment (alternative therapy): </i>
<b>SUBQ:</b> 0.4 mg/kg (maximum: 25 mg/dose) twice weekly for 8 weeks (in combination with methylprednisolone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18042798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18042798'])">Ref</a></span>) <b>or</b> 25 mg twice weekly (in combination with corticosteroids) for 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19443659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19443659'])">Ref</a></span>). <b>Note:</b> Guidelines recommend methylprednisolone or prednisolone be used alone for the initial treatment of acute graft-vs-host disease; current data are unable to determine which patients might benefit from intensified treatment (ie, the addition of an immunosuppressive agent, such as etanercept, with glucocorticoid therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22510384']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22510384'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46fc9b4b-22ea-4096-b090-0ebc9997e04a">Plaque psoriasis, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis, moderate to severe: SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 50 mg twice weekly for 3 months (starting doses of 25 or 50 mg once weekly have also been used successfully).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: 50 mg once weekly. <b>Note:</b> Some patients may require 50 mg twice weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30772098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30772098'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bfcea56-f4f1-4785-9277-8d2c90e99a99">Psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Once-weekly dosing:</i>
<b>SUBQ:</b> 50 mg once weekly (with or without concomitant methotrexate).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Twice-weekly dosing:</i>
<b>SUBQ:</b> 25 mg twice weekly (with or without concomitant methotrexate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10972371','lexi-content-ref-15248226','lexi-content-ref-16463435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10972371','lexi-content-ref-15248226','lexi-content-ref-16463435'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as an alternative to methotrexate in disease-modifying antirheumatic drug–naive patients with moderate to high disease activity, <b>or</b> as adjunctive therapy in patients who have not met treatment goals despite maximally tolerated methotrexate therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34101387']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34101387'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Once-weekly dosing:</i>
<b>SUBQ:</b> 50 mg once weekly (with or without methotrexate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187135'])">Ref</a></span>); maximum dose: 50 mg/week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Twice-weekly dosing:</i>
<b>SUBQ:</b> 25 mg twice weekly (with or without methotrexate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11096165','lexi-content-ref-12115173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11096165','lexi-content-ref-12115173'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7189c7a2-6c68-44b7-88e9-9e725ae13d68">Stevens-Johnson syndrome/toxic epidermal necrolysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stevens-Johnson syndrome/toxic epidermal necrolysis (off-label use): SUBQ: </b>25 mg (for weight ≤65 kg) <b>or</b> 50 mg (for weight &gt;65 kg) twice weekly in combination with glucocorticoids; discontinue when skin lesions heal or glucocorticoids are able to be tapered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35274741','lexi-content-ref-29400697','lexi-content-ref-35131514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35274741','lexi-content-ref-29400697','lexi-content-ref-35131514'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990500"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987798"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F167892"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F167901"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13284" href="/d/html/13284.html" rel="external">see "Etanercept (including biosimilars available in Canada): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> In Canada, Brenzys and Erelzi are approved as biosimilars to Enbrel (etanercept); approved uses and ages may vary; consult product labeling.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59cf387e-af6e-46ca-8974-9a4b9ad611bf">Familial Mediterranean fever; intolerance or resistance to colchicine</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Familial Mediterranean fever (FMF); intolerance or resistance to colchicine:</b> Very limited data available; efficacy results variable: Children ≥11 years and Adolescents: SUBQ: 0.8 mg/kg once weekly; maximum dose: 50 mg/dose; dosing based on a case series (n=3); results showed fewer attacks with treatment, median duration of therapy was 3 months and all patients continued colchicine therapy if able; over time, therapy was eventually changed to anakinra due to clinician determined unsatisfactory response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23276893','lexi-content-ref-21159830','lexi-content-ref-16956436','lexi-content-ref-23322405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23276893','lexi-content-ref-21159830','lexi-content-ref-16956436','lexi-content-ref-23322405'])">Ref</a></span>); a case series in adult patients (n=5, age range: 20 to 40 years) reported either no further attacks (80%) or a decrease in attack frequency (20%) with etanercept (25 mg twice weekly) therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21946459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21946459'])">Ref</a></span>). <b>Note:</b> Trials performed with Enbrel product.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bfa6a19-11be-4097-9456-7c7ce2ad756d">Juvenile idiopathic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Once-weekly dosing:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Weight &lt;63 kg: Enbrel: SUBQ: 0.8 mg/kg/dose once weekly; maximum dose: 50 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Weight ≥63 kg: Enbrel: SUBQ: 50 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Twice-weekly dosing:</i> Enbrel: SUBQ: 0.4 mg/kg/dose twice weekly, given 72 to 96 hours apart; maximum dose: 25 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16732547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16732547'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6fe2b10-99de-4c8b-b604-35f7e177c901">Juvenile psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile psoriatic arthritis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &lt;63 kg: Enbrel: SUBQ: 0.8 mg/kg/dose once weekly; maximum dose: 50 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight ≥63 kg: Enbrel: SUBQ: 50 mg once weekly.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c039e857-b3d8-4038-b368-8e66d2562ea6">Kawasaki disease; acute, adjunct therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kawasaki disease; acute, adjunct therapy:</b> Limited data available; efficacy results for IV immunoglobulin (IVIG) resistance variable by ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28356445','lexi-content-ref-31048415']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28356445','lexi-content-ref-31048415'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months, Children, and Adolescents: SUBQ: 0.8 mg/kg/dose for 3 doses; administer first dose immediately after completion of IVIG (day 0), then next 2 doses administered weekly (ie, the second dose at day 7, and third dose at day 14); maximum dose: 50 mg/dose; in all trials, patients also received standard aspirin therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20667551','lexi-content-ref-21392603','lexi-content-ref-31048415']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20667551','lexi-content-ref-21392603','lexi-content-ref-31048415'])">Ref</a></span>). Dosing based on a multi-center, phase 3, double-blind, placebo-controlled trial (EATAK) including 201 pediatric patients (n=100 etanercept treatment group; mean age: 3.77 ± 2.67 years [infant subgroup: n=15]) which showed that overall, etanercept did not significantly lower IVIG resistance compared to placebo (13% vs 22%, [p=0.1]). However, subgroup analysis demonstrated significantly lower IVIG resistance in patients &gt;1 year of age compared to placebo. Etanercept significantly reduced coronary z-scores in subjects with and without baseline dilatation, and coronary dilation progression compared to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31048415']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31048415'])">Ref</a></span>). <b>Note:</b> Trials performed with Enbrel product.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fb8c5f3-a1b3-4ba3-b517-cc8663ef3c7c">Plaque psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents &lt;18 years: <b>Note:</b> Results of a long-term study (264 weeks) showed efficacy maintained and therapy generally well-tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18199863','lexi-content-ref-20605256','lexi-content-ref-26775775','lexi-content-ref-20833444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18199863','lexi-content-ref-20605256','lexi-content-ref-26775775','lexi-content-ref-20833444'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &lt;63 kg: Enbrel: SUBQ: 0.8 mg/kg/dose once weekly; maximum dose: 50 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight ≥63 kg: Enbrel: SUBQ: 50 mg once weekly.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109287"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51109288"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F58862008"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Autoimmune disorder</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Auto<b>antibody development</b> may occur with the use of tumor necrosis factor (TNF) alpha inhibitors, including etanercept. Most frequently, autoantibodies include antinuclear antibody and anti–double-stranded DNA; less frequently, anti–extractable nuclear antigen, antihistone antibody, and anticardiolipin antibody (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126','lexi-content-ref-25110258','lexi-content-ref-16439435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126','lexi-content-ref-25110258','lexi-content-ref-16439435'])">Ref</a></span>). Frequency of autoantibody development varies depending on underlying disease, specific TNF alpha inhibitor medication, and the duration of use; the clinical significance of asymptomatic antibody positivity is unclear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25110258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25110258'])">Ref</a></span>). Antibody positivity may rarely result in the development of an autoimmune disorder, such as lupus-like syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25110258','lexi-content-ref-26768759','lexi-content-ref-16439435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25110258','lexi-content-ref-26768759','lexi-content-ref-16439435'])">Ref</a></span>). Symptoms may include arthralgia, myalgia, mucocutaneous symptoms (eg, <b>skin rash</b>), cytopenia, fatigue, fever, serositis, and kidney injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126','lexi-content-ref-25110258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126','lexi-content-ref-25110258'])">Ref</a></span>). Development of an autoimmune disorder is associated with a poor treatment response of the original disease to TNF alpha inhibitor therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126'])">Ref</a></span>). It is unclear if the development of an autoimmune disorder is a TNF alpha inhibitor class effect; several reports of rechallenge with the same TNF alpha inhibitor or a different TNF alpha inhibitor after treatment of the initial autoimmune disorder did not result in a recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25110258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25110258'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; postulated mechanisms include bystander activation of autoreactive lymphocytes due to drug-specific immunity, nonspecific activation of lymphocytes, direct cytotoxicity with release of autoantigens, and disruption of central T-cell tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15767026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15767026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Longer disease duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30412634','lexi-content-ref-12851868','lexi-content-ref-24185311']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30412634','lexi-content-ref-12851868','lexi-content-ref-24185311'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Ulcerative colitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Demyelinating disease</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New-onset or exacerbation of central and peripheral nervous system <b>demyelinating disease</b>, such as <b>multiple sclerosis</b>, <b>optic neuritis</b>, acute <b>transverse myelitis</b>, <b>Guillain-Barré syndrome</b>, and chronic inflammatory demyelinating polyneuropathy, may occur with tumor necrosis factor (TNF) alpha inhibitors, although causality has not been proven (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31921355','lexi-content-ref-33945946','lexi-content-ref-32421186','lexi-content-ref-17632266','lexi-content-ref-23287362','lexi-content-ref-33863839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31921355','lexi-content-ref-33945946','lexi-content-ref-32421186','lexi-content-ref-17632266','lexi-content-ref-23287362','lexi-content-ref-33863839'])">Ref</a></span>). Symptomatic CNS demyelination associated with TNF alpha inhibitors may be monophasic and/or clinically isolated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31845616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31845616'])">Ref</a></span>). Partial or complete resolution may occur after discontinuation of TNF alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11762947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11762947'])">Ref</a></span>); however, approximately one-third of TNF alpha inhibitors associated demyelinating episodes evolve into clinically definite multiple sclerosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30767720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30767720'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; several mechanisms have been postulated, including the following: May trigger CNS demyelination directly by immune activation in genetically and/or immunologically predisposed individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31845616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31845616'])">Ref</a></span>); may inhibit remyelination via TNF type-2 receptor (TNFR2) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9345421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9345421'])">Ref</a></span>); may increase ingress of auto-reactive T cells in the CNS; may alter downstream cytokine responses; may neutralize TNF systemically but not within the CNS, creating an artificially high local concentration of brain TNF (known as sponge effect); may permit latent CNS viral infection; or may promote anti-drug antibodies and immune complexes that are contributory to demyelination events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28337644','lexi-content-ref-25169849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28337644','lexi-content-ref-25169849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; mean time of exposure to TNF alpha inhibitors before onset of symptoms: 18 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28337644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28337644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting or recent onset of central or peripheral nervous system demyelinating disease</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various cutaneous eruptions have been reported with etanercept, including <b>psoriasiform eruption</b> (either new onset or exacerbation), hidradenitis suppurativa, <b>lupus-like syndrome</b>, <b>eczematous rash</b>, <b>erythema nodosum</b>, <b>bullous pemphigoid</b>, <b>lichenoid eruption</b>, and <b>Henoch-Schönlein purpura</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23198006','lexi-content-ref-29859201','lexi-content-ref-17853314','lexi-content-ref-17310002','lexi-content-ref-26965410','lexi-content-ref-31240749','lexi-content-ref-28737221','lexi-content-ref-35694729','lexi-content-ref-36412234','lexi-content-ref-17300238','lexi-content-ref-29611085','lexi-content-ref-28854831','lexi-content-ref-28468732','lexi-content-ref-17632266','lexi-content-ref-32135533','lexi-content-ref-11867114','lexi-content-ref-21752492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23198006','lexi-content-ref-29859201','lexi-content-ref-17853314','lexi-content-ref-17310002','lexi-content-ref-26965410','lexi-content-ref-31240749','lexi-content-ref-28737221','lexi-content-ref-35694729','lexi-content-ref-36412234','lexi-content-ref-17300238','lexi-content-ref-29611085','lexi-content-ref-28854831','lexi-content-ref-28468732','lexi-content-ref-17632266','lexi-content-ref-32135533','lexi-content-ref-11867114','lexi-content-ref-21752492'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Psoriasiform eruptions: Non–dose-related; possibly related to cytokine imbalance or imbalance between tumor necrosis factor (TNF) alpha and interferon-alpha (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22515220','lexi-content-ref-34625145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22515220','lexi-content-ref-34625145'])">Ref</a></span>). Lupus-like syndrome: Non–dose-related; possibly related to cytokine imbalance; development of autoantibodies typically associated with lupus may occur without clinical symptoms in patients treated with etanercept and other TNF alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23198006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23198006'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Psoriasiform eruptions: Delayed; ~10 months (range: 2 to 62 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34402108','lexi-content-ref-17310002','lexi-content-ref-34625145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34402108','lexi-content-ref-17310002','lexi-content-ref-34625145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Females (psoriatic lesions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093599'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (palmoplantar pustulosis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29859201']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29859201'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity data among TNF alpha inhibitors in patients who develop psoriatic lesions are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34402108','lexi-content-ref-34625145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34402108','lexi-content-ref-34625145'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Heart failure</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New-onset <b>heart failure</b> (HF) and worsening of HF have been reported with tumor necrosis factor (TNF) alpha inhibitors, including etanercept; however, data are conflicting, and risk is unclear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21328309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21328309'])">Ref</a></span>). Rheumatoid arthritis (RA) may be a risk factor for HF development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15692992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15692992'])">Ref</a></span>). Some data suggest that TNF alpha inhibitors may reduce the risk of HF in the RA population by improving inflammation, lowering disease activity, and improving surrogate markers of cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20038753','lexi-content-ref-34496051','lexi-content-ref-20472597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20038753','lexi-content-ref-34496051','lexi-content-ref-20472597'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; postulated mechanisms include pro-inflammatory cytokine activation, accelerated atherosclerosis, and reduced physical activity related to the underlying rheumatologic disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24093840','lexi-content-ref-16981296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24093840','lexi-content-ref-16981296'])">Ref</a></span>). “Reverse signaling” may occur, leading to cardiotoxic effects; TNF on cardiomyocytes of the failing heart may act as receptors, activating intracellular signaling pathways, potentiating the toxic effect of the cytokine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10843670','lexi-content-ref-23557269','lexi-content-ref-29895751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10843670','lexi-content-ref-23557269','lexi-content-ref-29895751'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median 8.5 months (range: 5 to 17 months [data with infliximab]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12755552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12755552'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting HF</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher disease activity (inflammation) (eg, disease activity score [DAS28], C-reactive protein, erythrocyte sedimentation rate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24458537','lexi-content-ref-21216812','lexi-content-ref-25609412','lexi-content-ref-25776112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24458537','lexi-content-ref-21216812','lexi-content-ref-25609412','lexi-content-ref-25776112'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatitis B reactivation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Reactivation of hepatitis B virus (HBV) may occur with immunosuppressive or biologic therapy, including tumor necrosis factor (TNF) alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>). <b>Reactivation of HBV</b> may occur in patients who are HBsAg-positive and in patients who are HBsAg-negative/HBcAb-positive with detectable HBV DNA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21719446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21719446'])">Ref</a></span>). Criteria for HBV reactivation includes (1) a rise in HBV DNA compared to baseline (or an absolute level of HBV DNA when a baseline is unavailable) and (2) reverse seroconversion (seroreversion) from HBsAg-negative to HBsAg-positive for patients who are HBsAg-negative and anti-HBc–positive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Inhibit stimulation of HBV-specific T lymphocytes, promoting reactivation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21719446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21719446'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; 2 weeks after initiation, up to a year after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Presence of cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> High baseline HBV DNA level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> HBeAg or HBsAg seropositivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Absence of anti-HBs among patients with resolved HBV infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Chronic HBV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Non-A HBV genotype (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Hepatitis C, hepatitis D, or HIV co-infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Etanercept has been associated with <b>increased serum transaminases</b> and <b>hepatotoxicity</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32944048','lexi-content-ref-32025603','lexi-content-ref-22941219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32944048','lexi-content-ref-32025603','lexi-content-ref-22941219'])">Ref</a></span>). <b>Cholestatic hepatitis</b>, <b>reactivation of hepatitis B virus</b> (HBV), exacerbation of hepatitis E virus infection, and <b>autoimmune hepatitis</b> have been reported with etanercept and other tumor necrosis factor (TNF) alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30637218','lexi-content-ref-27836355','lexi-content-ref-18824922','lexi-content-ref-31855274','lexi-content-ref-18563514','lexi-content-ref-18433400','lexi-content-ref-32025603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30637218','lexi-content-ref-27836355','lexi-content-ref-18824922','lexi-content-ref-31855274','lexi-content-ref-18563514','lexi-content-ref-18433400','lexi-content-ref-32025603'])">Ref</a></span>). Elevated aminotransferases between 2 to 3 times the upper limit of normal may occur that are usually transient and asymptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32025603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32025603'])">Ref</a></span>). Resolution of symptoms in patients who develop an autoimmune hepatitis may require initiation of corticosteroid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37001957','lexi-content-ref-25131534','lexi-content-ref-23333219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37001957','lexi-content-ref-25131534','lexi-content-ref-23333219'])">Ref</a></span>). Immunomodulatory use, in particular methotrexate, may decrease the risk of hepatotoxicity associated with TNF alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25131534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25131534'])">Ref</a></span>). Patients often tolerate a different TNF alpha inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25131534','lexi-content-ref-26692395','lexi-content-ref-19505409']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25131534','lexi-content-ref-26692395','lexi-content-ref-19505409'])">Ref</a></span>); although, hepatotoxicity may recur with an alternative agent in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22662786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22662786'])">Ref</a></span>). Hepatotoxicity is more commonly associated with infliximab compared to etanercept and other TNF alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26692395','lexi-content-ref-23333219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26692395','lexi-content-ref-23333219'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29564668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29564668'])">Ref</a></span>) or autoimmunity due to development of autoantibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32025603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32025603'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; ranges from 2 weeks to several years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32025603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32025603'])">Ref</a></span>). Autoimmune hepatitis has a longer latency period than non-immune cases (16 weeks vs 10 weeks, respectively) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23333219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23333219'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher body mass index (elevated liver enzymes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22941219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22941219'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tumor necrosis factor (TNF) alpha inhibitors may be associated with <b>infection</b>, including <b>serious infection</b>. In clinical trials, serious infections were numerically higher among patients treated with TNF alpha inhibitors than among patients who received placebo. Meta-analyses and observational studies have reported inconsistency in risk. One study reported an increase in serious infection in patients treated with TNF alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16705109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16705109'])">Ref</a></span>). Another study found no increase in risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18753157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18753157'])">Ref</a></span>). An observational study did not demonstrate an increased infection risk among patients receiving TNF alpha inhibitors vs comparators (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22056398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22056398'])">Ref</a></span>). Infections may present as disseminated (rather than local) disease. <b>Tuberculosis</b> disease (including reactivation of tuberculosis infection), invasive <b>fungal infection</b> (including <b>aspergillosis</b>, <b>blastomycosis</b>, <b>candidiasis</b>, <b>coccidioidomycosis</b>, <b>histoplasmosis</b>, and pneumocystosis), and <b>bacterial infection</b>, <b>viral infection</b>, or <b>other opportunistic infections</b> (including legionellosis and listeriosis) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; TNF alpha is important in the immune response against infections, suggesting that medications that inhibit TNF alpha may increase the risk of infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21328309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21328309'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18753157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18753157'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21791449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21791449'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic lung or kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21791449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21791449'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent immunosuppressants (eg, corticosteroids, methotrexate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22056398','lexi-content-ref-30876964','lexi-content-ref-21791449','lexi-content-ref-16447241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22056398','lexi-content-ref-30876964','lexi-content-ref-21791449','lexi-content-ref-16447241'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of an opportunistic infection</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic or recurrent infection</p>
<p style="text-indent:-2em;margin-left:6em;">• Conditions that predispose to infections (eg, advanced or poorly controlled diabetes)</p>
<p style="text-indent:-2em;margin-left:6em;">• Residence/travel in areas of endemic tuberculosis or mycoses (blastomycosis, coccidioidomycosis, histoplasmosis)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Injection-site reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Etanercept is associated with <b>injection-site reactions</b>; recall reactions (local reactions at the site of previous injections) may also occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28260984','lexi-content-ref-23330811','lexi-content-ref-28110056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28260984','lexi-content-ref-23330811','lexi-content-ref-28110056'])">Ref</a></span>). Irritative reactions do not require discontinuation and resolve spontaneously over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22998733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22998733'])">Ref</a></span>). Cross-reactivity between tumor necrosis factor (TNF) alpha inhibitors is not well described. Etanercept has been tolerated in patients with previous infusion reactions with infliximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16265699','lexi-content-ref-16837489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16265699','lexi-content-ref-16837489'])">Ref</a></span>). In contrast, there are reports of patients who developed hypersensitivity reactions to etanercept and at least one other TNF alpha inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30006049','lexi-content-ref-22289732','lexi-content-ref-16490850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30006049','lexi-content-ref-22289732','lexi-content-ref-16490850'])">Ref</a></span>). There is a decreased risk with concurrent immunomodulator therapy (eg, methotrexate, cyclosporine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28260984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28260984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28110056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28110056'])">Ref</a></span>) or IgE mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25725941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25725941'])">Ref</a></span>). Irritative reactions may result from improper injection technique or excipients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22998733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22998733'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; reactions generally occur on the fourth injection, with an onset 1 to 2 days after injection and last 2 to 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28110056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28110056'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28260984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28260984'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased pain associated with etanercept single-use syringes vs etanercept in vials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30412634']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30412634'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant lymphoma</b> and other <b>malignant neoplasms</b> (some fatal) have been reported in children and adolescents receiving tumor necrosis factor (TNF) alpha inhibitors, including etanercept. Half of the malignancies reported in children and adolescents were lymphomas (<b>Hodgkin lymphoma</b> and <b>non-Hodgkin lymphoma</b>), while other cases varied and included rare malignancies usually associated with immunosuppression and malignancies not typically observed in this population. Most patients were receiving concomitant immunosuppressants.</p>
<p style="text-indent:-2em;margin-left:2em;">Long-term observational studies and meta-analyses indicate no association between TNF alpha inhibitor therapy and an overall increased risk of cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15829572','lexi-content-ref-30289537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15829572','lexi-content-ref-30289537'])">Ref</a></span>). One study reported a significant increase in lymphomas in patients with rheumatoid arthritis (RA) receiving TNF alpha inhibitors compared to the general population. However, there was no significant increased risk of lymphomas in patients receiving TNF alpha inhibitors compared to those receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or with dose, increasing time since initiation, or cumulative duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18467516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18467516'])">Ref</a></span>). Another study reported no difference in the risk of solid tumors in patients with RA receiving TNF alpha inhibitors compared to those receiving csDMARDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24685910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24685910'])">Ref</a></span>). Other studies reported no increased risk of malignancy recurrence in patients receiving TNF alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25107559','lexi-content-ref-20064207']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25107559','lexi-content-ref-20064207'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May contribute to pro-tumor activity and suppress the anti-tumor response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29593717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29593717'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; median 30 months (range: 1 to 84 months).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tuberculosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Adult and pediatric patients treated with tumor necrosis factor (TNF) alpha inhibitors are at risk for developing <b>tuberculosis</b> (TB) disease (including <b>reactivated tuberculosis</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980'])">Ref</a></span>). A meta-analysis of randomized controlled trials (RCTs) of TNF alpha inhibitors vs control and registry/longitudinal cohort studies of TNF alpha inhibitors vs other disease-modifying antirheumatic drugs (DMARDs) found a significant increase in TB risk in patients with rheumatoid arthritis treated with TNF alpha inhibitors. In the non-RCTs, incidence rates with adalimumab were higher than etanercept. Preventive treatment for latent TB infection reduced TB risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472414'])">Ref</a></span>). In the RCTs, no difference in TB rates were found; however, the failure to detect a difference in TB rates between the 2 groups may be due to a short observational period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> TNF alpha inhibitors interfere with TNF alpha induction of the granuloma, which is a crucial defense mechanism in controlling TB (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980'])">Ref</a></span>). TNF alpha inhibitors modulate T-cell number, function, and cytokine signaling, important for the control of TB infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980','lexi-content-ref-9826720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980','lexi-content-ref-9826720'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median 3 to ~73 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Residence in an area with high TB prevalence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Known TB exposure or ongoing risk factors for TB exposure (eg, travel to areas with high TB prevalence; residence in correctional facilities, long-term care facilities, or homeless shelters; certain healthcare workers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10881762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10881762'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F167861"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-rash')">table 1</a>)</span><span class="table-link" style="display:none;">Skin Rash</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Rash" frame="border" id="lexi-content-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Etanercept: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Etanercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Etanercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">876</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">359</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">415</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">217</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (3% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Positive ANA titer (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (non-neutralizing; 4% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (including bacterial infection, fungal infection, serious infection, viral infection: 27% to 81%)<span class="lexi-table-link-container"> (<a aria-label="Infection table link" class="lexi-table-link" data-table-id="lexi-content-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infection')">table 2</a>)</span><span class="table-link" style="display:none;">Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infection" frame="border" id="lexi-content-infection" rules="all">
<caption style="text-align:center;">
<b>Etanercept: Adverse Reaction: Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Etanercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Etanercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">876</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">359</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">81%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">415</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">217</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">50%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (children and adolescents: 7%; adults: 15% to 43%; mild to moderate; usually decreases with subsequent injections)<span class="lexi-table-link-container"> (<a aria-label="Injection-Site Reaction table link" class="lexi-table-link" data-table-id="lexi-content-injection-site-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-injection-site-reaction')">table 3</a>)</span><span class="table-link" style="display:none;">Injection-Site Reaction</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Injection-Site Reaction" frame="border" id="lexi-content-injection-site-reaction" rules="all">
<caption style="text-align:center;">
<b>Etanercept: Adverse Reaction: Injection-Site Reaction</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Etanercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Etanercept)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Methotrexate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">876</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">359</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">43%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">415</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">217</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">37%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory tract infection (21% to 54%), upper respiratory tract infection (38% to 65%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2% to 5%), urticaria (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, leukemia, malignant lymphoma, pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Autoimmune hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Reactivation of HBV, varicella zoster infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aseptic meningitis, demyelinating disease of the central nervous system</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus-like syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Tuberculosis (including pulmonary and extrapulmonary)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis, malignant melanoma, skin carcinoma</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastroenteritis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Malignant neoplasm</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess, influenza, opportunistic infection, sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Osteomyelitis, septic arthritis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Pyelonephritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, pneumonia, reactivated tuberculosis, sinusitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, vasculitis (Pérez-De-Lis 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Havmose 2017), bullous pemphigoid (Shmidt 2012), cutaneous lupus erythematosus, eczematous rash (Lee 2007), erythema multiforme, erythema nodosum (Kurokami 2023), lichenoid eruption (Havmose 2017), Merkel cell carcinoma (de Giorgi 2011), psoriasiform eruption (Shmidt 2012), psoriasis (including palmoplantar) (Shmidt 2012), psoriasis flare (Shmidt 2012), pustular psoriasis (Shmidt 2012), Stevens-Johnson syndrome, subcutaneous nodule, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Inflammatory bowel disease (van Dijken 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, hematologic abnormality (macrophage activation syndrome), Henoch-Schönlein purpura (Shmidt 2012), Hodgkin lymphoma, leukopenia, lymphadenopathy, neutropenia (Pérez-De-Lis 2017), non-Hodgkin lymphoma, thrombocytopenia (Pérez-De-Lis 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Shah 2020), hepatotoxicity (Chalasani 2021), increased serum transaminases (Shah 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Sendur 2009), hypersensitivity angiitis (Ramos-Casals 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Sarcoidosis (Pérez-De-Lis 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Aspergillosis, atypical mycobacterial infection, blastomycosis, candidiasis, coccidioidomycosis, herpes zoster infection, histoplasmosis, protozoal infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Guillain-Barré syndrome, headache, multiple sclerosis, paresthesia, seizure, transverse myelitis (Havmose 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis (Ramos-Casals 2010), scleritis (Sassa 2012), uveitis (Pérez-De-Lis 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial lung disease (Pérez-De-Lis 2017), pneumonia due to <i>Pneumocystis jirovecii</i></p></div>
<div class="block coi drugH1Div" id="F167873"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Sepsis</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to etanercept or any component of the formulation; patients at risk of sepsis syndrome (eg, immunocompromised, HIV positive)</p></div>
<div class="block war drugH1Div" id="F167858"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Allergic reactions may occur, if an anaphylactic reaction or other serious allergic reaction occurs, administration should be discontinued immediately and appropriate therapy initiated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Formation of neutralizing anti-drug antibodies may occur with biologic tumor necrosis factor (TNF) inhibitors and may be associated with loss of efficacy (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome or autoimmune hepatitis, have been reported; monitor and discontinue if symptoms develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Demyelinating CNS disease: Rare cases of new-onset or exacerbation of CNS demyelinating disorders have occurred; may present with mental status changes and some may be associated with permanent disability. Optic neuritis, transverse myelitis, multiple sclerosis, Guillain-Barré syndrome, and other peripheral demyelinating neuropathies have been reported. Use with caution in patients with preexisting or recent-onset CNS demyelinating disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Worsening and new-onset heart failure has been reported, including in patients without known preexisting cardiovascular disease. Use with caution in patients with heart failure or decreased left ventricular function. In a scientific statement from the American Heart Association, TNF blockers have been determined to be agents that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic disorders: Rare cases of pancytopenia and aplastic anemia have been reported (some fatal). Patients must be advised to seek medical attention if they develop signs and symptoms suggestive of blood dyscrasias; discontinue if significant hematologic abnormalities are confirmed. Use with caution in patients with a history of significant hematologic abnormalities.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatitis B: Rare reactivation of hepatitis B (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants (has been fatal); evaluate for HBV prior to initiation in all patients. Monitor during and for several months following discontinuation of treatment in HBV carriers; consider interruption of therapy if reactivation occurs and treat appropriately with antiviral therapy. If resumption of therapy is deemed necessary, exercise caution and monitor patient closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: <b>[US Boxed Warning]: Patients receiving etanercept are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate, corticosteroids) and may present as disseminated (rather than local) disease. Tuberculosis (TB) disease (including reactivation of TB infection [latent TB]), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral, or other opportunistic infections (including Legionellosis and Listeriosis) have been reported. Monitor closely for signs/symptoms of infection during and after treatment. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to initiating therapy in patients with chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infections who develop severe systemic illness.</b> Caution should be exercised when considering use in elderly patients, patients with chronic or recurrent infections, patients exposed to TB, patients with a history of an opportunistic infection, in patients with conditions that predispose them to infections (eg, advanced or poorly controlled diabetes), residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent infections. Do not initiate etanercept therapy in patients with an active infection, including clinically important localized infection. Patients who develop a new infection while undergoing treatment should be monitored closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: <b>[US Boxed Warning]: Lymphoma and other malignancies (some fatal) have been reported in children and adolescents receiving TNF-blocking agents, including etanercept.</b> Half of the malignancies reported in children and adolescents were lymphomas (Hodgkin and non-Hodgkin) while other cases varied and included rare malignancies usually associated with immunosuppression and malignancies not typically observed in this population. The impact of etanercept on the development and course of malignancy is not fully defined. Compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma and leukemia. Lymphomas and other malignancies were also observed (at rates higher than expected for the general population) in adult patients receiving etanercept. Hepatosplenic T-cell lymphoma, a rare T-cell lymphoma, has also been associated with TNF-blocking agents, primarily reported in adolescent and young adult males with Crohn disease or ulcerative colitis. Melanoma, nonmelanoma skin cancer, and Merkel cell carcinoma have been reported. Perform periodic skin examinations in all patients during therapy, particularly those at increased risk of skin cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tuberculosis: <b>[US Boxed Warning]: TB disease (active TB) (disseminated or extrapulmonary), including reactivation of TB infection (latent TB), has been reported in patients receiving etanercept.</b>
<b> Evaluate patients for TB risk factors and TB infection (with a tuberculin skin test) prior to and during therapy. Treatment for TB infection should be initiated before use. </b>
<b>Patients with initial negative tuberculin skin tests should receive continued monitoring for TB during and after treatment. </b> Consider antituberculosis treatment if an adequate course of treatment cannot be confirmed in patients with a history of TB infection or disease or with risk factors despite negative skin test. Some patients who tested negative prior to therapy have developed active infection; tests for TB infection may be falsely negative while on etanercept therapy. Use with caution in patients who have traveled to or resided in regions where TB is endemic. Monitor for signs and symptoms of TB in all patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alcoholic hepatitis: Use with caution in patients with moderate to severe alcoholic hepatitis. Compared to placebo, the mortality rate in patients treated with etanercept was similar at 1 month but significantly higher after 6 months.</p>
<p style="text-indent:-2em;margin-left:4em;">• Granulomatosis with polyangiitis: Use is not recommended in patients with granulomatosis with polyangiitis who are receiving immunosuppressive therapy due to higher incidence of noncutaneous solid malignancies.</p>
<p style="text-indent:-2em;margin-left:4em;">• HIV: Use with caution in HIV-positive patients; TNF-α inhibitors may be appropriate in patients receiving highly active antiretroviral therapy, provided they have normal CD4 counts, no viral load, and no recent opportunistic infections (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizures; new-onset or exacerbation of seizures have been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Infection has been reported at a higher incidence; use caution in elderly patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold biologic disease-modifying antirheumatic drugs (DMARDs) prior to surgery and plan surgery after the next dose is due. Surgery can occur after holding medication for 1 full dosing cycle (eg, for medications administered every 4 weeks, schedule surgery 5 weeks from last administered dose); therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk). Decisions to withhold therapy should be based on shared decision making; ensure the patient and their provider weigh risks of interrupting therapy and disease control versus risks of continuing therapy and surgical complications (ACR/AAHKS [Goodman 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Malignancies have been reported among children and adolescents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Varicella virus exposure: Patients with a significant exposure to varicella virus should temporarily discontinue therapy; treatment with varicella zoster immune globulin should be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Diluent for injection may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Some dosage forms may contain dry natural rubber (latex). <b>Note:</b> As of June 2023, the Enbrel prescribing information states that the devices are no longer made with natural rubber latex.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878448"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In patients with juvenile idiopathic arthritis, rare inflammatory bowel disease has been reported (van Dijken 2011); monitor and discontinue therapy if symptoms develop.</p></div>
<div class="block prod-avail drugH1Div" id="F48847984"><span class="drugH1">Product Availability</span>
<p style="text-indent:-2em;margin-left:2em;">Erelzi (etanercept-szzs): FDA approved August 2016; anticipated availability is currently unknown. Erelzi is approved as biosimilar to Enbrel, but not as an interchangeable product.</p>
<p style="text-indent:-2em;margin-left:2em;">Eticovo (etanercept-ykro): FDA approved April 2019; anticipated availability is currently unknown. Eticovo is approved as biosimilar to Enbrel, but not as an interchangeable product.</p></div>
<div class="block foc drugH1Div" id="F167868"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Enbrel: 25 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Enbrel SureClick: 50 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Enbrel Mini: 50 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Enbrel: 25 mg/0.5 mL (0.5 mL); 50 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Enbrel: 25 mg (1 ea [DSC]) [contains benzyl alcohol]</p></div>
<div class="block geq drugH1Div" id="F167854"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F167875"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Enbrel Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/0.5 mL (per 0.5 mL): $1,110.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Enbrel SureClick Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $2,220.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Cartridge</b> (Enbrel Mini Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $2,220.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Enbrel Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/0.5 mL (per 0.5 mL): $1,110.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $2,220.55</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866802"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Brenzys: 50 mg/mL (0.98 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erelzi: 50 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Brenzys: 50 mg/mL (0.98 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Enbrel: 50 mg/mL (0.98 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erelzi: 25 mg/0.5 mL (0.5 mL); 50 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Enbrel: 25 mg ([DSC]) [contains benzyl alcohol, tromethamine]</p></div>
<div class="block adm drugH1Div" id="F167870"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Administer subcutaneously. Rotate injection sites; may inject into the thigh (preferred), abdomen (avoiding the 2-inch area around the navel), or outer areas of upper arm. New injections should be given at least 1 inch from an old site and never into areas where the skin is tender, bruised, red, or hard; any raised thick, red, or scaly skin patches or lesions; or areas with scars or stretch marks. For a more comfortable injection, allow autoinjectors, prefilled syringes, single-dose vials, and dose trays to reach room temperature for 15 to 30 minutes (≥30 minutes for autoinjector) prior to injection; do not remove the needle cover while allowing product to reach room temperature. There may be small white particles of protein in the solution; this is not unusual for proteinaceous solutions. <b>Note:</b> If the health care provider determines that it is appropriate, patients may self-inject after proper training in injection technique.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional formulation-specific administration information:</p>
<p style="text-indent:-2em;margin-left:4em;">Single-dose vials: Withdraw contents from vial using a 22-gauge 1½ inch needle attached to a 1 mL syringe; after withdrawing vial contents, remove needle and replace with 27-gauge ½ inch needle to administer the injection. Use the same syringe if 2 vials are needed to achieve the total dose.</p></div>
<div class="block admp drugH1Div" id="F52612756"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Administer subcutaneously into front of the thigh (preferred), abdomen (avoiding the area around the navel [2 inches in adults]), or outer area of the upper arm. Rotate injection sites. New injections should be administered at least 1 inch from an old site and never into areas where the skin is tender, bruised, red, or hard or into any raised thick, red, or scaly skin patches or lesions. For a more comfortable injection, autoinjectors, prefilled syringes, and dose trays may be allowed to reach room temperature by removing from the refrigerator 15 to 30 minutes prior to injection (≥30 minutes for autoinjector). <b>Note:</b> If the prescriber determines that it is appropriate, patients or caregivers may self-inject or inject, respectively, after proper training in injection technique.</p>
<p style="text-indent:-2em;margin-left:2em;">Multiple-use vial (Enbrel): Visually inspect for particulate matter and discoloration prior to administration; solution should not be used if cloudy, discolored, or if particulate is present. Do not administer &gt;25 mg at a single injection site if the multiple-use vial is used to prepare the dose; use a 27-gauge needle for injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Single-dose vial (Enbrel): Do not remove vial cap while allowing to reach room temperature. Visually inspect for particulate matter and discoloration prior to administration; solution may have small white particles of protein, which is normal for a proteinaceous solution; solution should not be used if cloudy, discolored, or if foreign matter is present. Use a 22-gauge needle for withdrawing solution from vial(s); the same syringe may be used if more than 1 vial is required for the dose; use a 27-gauge needle for injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Single-use prefilled syringe or autoinjector (Enbrel): Do not remove needle cover or needle shield (syringe) or purple cap (autoinjector) while allowing to reach room temperature. Visually inspect for particulate matter and discoloration prior to administration; solution may have small white particles of protein, which is normal for a proteinaceous solution; solution should not be used if cloudy, discolored or if foreign matter is present.</p></div>
<div class="block meg drugH1Div" id="F7874648"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F103795s5594lbl.pdf%23page%3D35&amp;token=gIgKK1%2FPhunfXjEnW2yLvZDKOPTWQvBUZj0nrrfeRLEF5G0jfY9TfuciYHmrp0HchddFo7yx4kugyWWCmGG7LU5tb7j6KkdfpUHbqxy%2FMkh7bHJ5MV7kjKFgK8HnXeoA&amp;TOPIC_ID=8925" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103795s5594lbl.pdf#page=35</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F167869"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ankylosing spondylitis:</b> Reducing signs and symptoms in patients with active ankylosing spondylitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile psoriatic arthritis:</b> Treatment of active juvenile psoriatic arthritis in pediatric patients ≥2 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis:</b> Treatment of patients ≥4 years of age with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Polyarticular juvenile idiopathic arthritis:</b> Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ≥2 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis:</b> Reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adults with psoriatic arthritis. Etanercept can be used with or without methotrexate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis:</b> Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. Etanercept can be initiated in combination with methotrexate or used alone.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>In Canada, Brenzys and Erelzi are approved as biosimilars to Enbrel (etanercept); refer to Canadian product monograph(s) for biosimilar-specific indication details.</p></div>
<div class="block off-label drugH1Div" id="F25473874"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute graft-vs-host disease (treatment); Nonradiographic axial spondyloarthritis; Stevens-Johnson syndrome/toxic epidermal necrolysis</p></div>
<div class="block mst drugH1Div" id="F7914269"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Enbrel may be confused with Levbid</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299288"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F167863"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abatacept: Anti-TNF Agents may enhance the immunosuppressive effect of Abatacept. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anifrolumab: Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) may enhance the immunosuppressive effect of Anifrolumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belimumab: May enhance the immunosuppressive effect of Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Management: Consider alternatives to the use of belimumab with other biologic therapies. Monitor closely for increased toxicities related to additive immunosuppression (ie, infection, malignancy) if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Biologic Disease-Modifying Antirheumatic Drugs (DMARDs): May enhance the immunosuppressive effect of other Biologic Disease-Modifying Antirheumatic Drugs (DMARDs).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: Etanercept may enhance the adverse/toxic effect of CycloPHOSphamide. An increased risk of solid cancer development may be present. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53703313"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The American Academy of Dermatology considers tumor necrosis factor alpha (TNFα) blocking agents for the treatment of psoriasis to be compatible for use in male patients planning to father a child (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:0em;margin-top:2em;">Females with well-controlled psoriasis planning a pregnancy who wish to avoid fetal exposure can consider discontinuing etanercept 15 days prior to attempting pregnancy (Rademaker 2018).</p></div>
<div class="block pri drugH1Div" id="F167876"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Etanercept crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Following in utero exposure, etanercept concentrations in the newborn at delivery are 3% to 32% of the maternal serum concentration. A case report describes maternal use of subcutaneous etanercept 25 mg twice weekly throughout pregnancy. Maternal concentrations remained stable throughout each trimester. Maternal and cord blood concentrations at delivery were 2,239 ng/mL and 81 ng/mL, respectively. Etanercept concentrations in the neonate were 21 ng/mL, 1 week after delivery and not detectable 12 weeks later even though the child was breastfed and etanercept was present in breast milk (3.5 ng/mL) (Murashima 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome information following maternal use of etanercept in pregnancy is available. Information related to this class of medications is emerging, but based on available data, tumor necrosis factor alpha (TNFα) blocking agents are considered to have low to moderate risk when used in pregnancy (ACOG 776 2019).</p>
<p style="text-indent:0em;margin-top:2em;">The risk of immunosuppression may be increased following third trimester maternal use of TNFα blocking agents; the fetus, neonate/infant should be considered immunosuppressed for 1 to 3 months following in utero exposure (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:0em;margin-top:2em;">Use of immune modulating therapies in pregnancy should be individualized to optimize maternal disease and pregnancy outcomes (ACOG 776 2019). The American Academy of Dermatology considers TNFα blocking agents for the treatment of psoriasis to be compatible with pregnancy (AAD-NPF [Menter 2019]).</p></div>
<div class="block brc drugH1Div" id="F167877"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Etanercept is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">A case report describes use of SubQ etanercept 25 mg twice weekly starting 4 weeks' postpartum. In samples obtained 1 day after the fifth maternal dose (postpartum day 45), concentrations of etanercept in the breast milk and maternal serum were 75.4 ng/mL and 2,057.6 ng/mL, respectively. The infant was not breastfed (Ostensen 2004). SubQ etanercept was initiated 3 months' postpartum in a woman who was already breastfeeding her infant. Peak breast milk concentrations (7.5 ng/mL) occurred 72 hours after a 50 mcg once weekly dose (Keeling 2010). A third case report describes maternal use of etanercept 25 mg SubQ once weekly beginning the second trimester of pregnancy and continuing postpartum while breastfeeding her infant. Breast milk concentrations on postpartum day 41 (1 day after a maternal dose) were 3 ng/mL, increasing to 5 ng/mL on postpartum day 43, then decreasing to &lt;2 ng/mL prior to the next maternal dose (postpartum day 47). Etanercept in the infant serum was less than the limit of detection (&lt;4 ng/mL) when sampled on days 42 through 43 postpartum (Berthelsen 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. However, tumor necrosis factor alpha (TNFα) blocking agents are considered compatible with breastfeeding (AAD-NPF [Menter 2019]; ACOG 776 2019).</p></div>
<div class="block mop drugH1Div" id="F6045563"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential (baseline); complete metabolic panel (baseline); tuberculosis (TB) screening prior to initiating and during therapy (chest X-ray if TB positive); hepatitis B virus (HBV)/hepatitis C virus screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); HIV screening (baseline) (AAD-NPF [Menter 2019]); signs/symptoms of infection, heart failure, hypersensitivity reaction, lupus-like syndrome, or malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss). Monitor improvement of symptoms and physical function assessments.</p></div>
<div class="block pha drugH1Div" id="F167857"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Etanercept is a recombinant DNA-derived protein composed of tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Etanercept binds tumor necrosis factor (TNF) and blocks its interaction with cell surface receptors. TNF plays an important role in the inflammatory processes and the resulting joint pathology of rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), and plaque psoriasis.</p></div>
<div class="block phk drugH1Div" id="F167872"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: ~2 to 3 weeks; RA: 1 to 2 weeks, weeks, with maximum effect at 3 months; Psoriasis: Response best determined after 3 to 4 months (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Absorbed slowly after SUBQ injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: 60%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: SUBQ: Children ≥4 years and Adolescents (JIA): Mean range: 70 to 94.8 hours (range: 31.2 to 104.8 hours) (Yim 2005); Adults (RA): 102 ± 30 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: RA: SUBQ: 69 ± 34 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: Children and Adolescents 4 to 17 years: 46 mL/hour/m<sup>2 </sup>(Enbrel prescribing information 1998); Adults: 160 ± 80 mL/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F167878"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Enbrel | Enerceptan | Erelzi</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Brenzys | Enbrel</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi | Nepexto</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bio manguinhos etanercepte | Brenzys | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi | Nepexto</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Enbrel | Erelzi | Exadia</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Erelzi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Erelzi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi | Nepexto</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi | Nepexto</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Erelzi</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi | Nepexto</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Erelzi</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi | Nepexto</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Etacept</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Erelzi</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Enbrel | Enbrel myclic | Etoloce | Etoloche | Eucept</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Erelzi</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Brenzys | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Benepali | Erelzi</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Nepexto</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Enbrel | Erelzi</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Enbrel</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Enbrel | Erelzi | Nepexto</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472414">
<a name="26472414"></a>Ai JW, Zhang S, Ruan QL, Yu YQ, Zhang BY, Liu QH, Zhang WH. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. <i>J Rheumatol</i>. 2015;42(12):2229-2237. doi:10.3899/jrheum.150057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/26472414/pubmed" id="26472414" target="_blank">26472414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23276893">
<a name="23276893"></a>Akgul O, Kilic E, Kilic G, et al, "Efficacy and Safety of Biologic Treatments in Familial Mediterranean Fever," <i>Am J Med Sci</i>, 2012, Dec 28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/23276893/pubmed" id="23276893" target="_blank">23276893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23198006">
<a name="23198006"></a>Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. Anti-tumor necrosis factor-α induced systemic lupus erythematosus. <i>Open Rheumatol J</i>. 2012;6:315-319. doi:10.2174/1874312901206010315<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/23198006/pubmed" id="23198006" target="_blank">23198006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19443659">
<a name="19443659"></a>Alousi AM, Weisdorf DJ, Logan BR, et al; Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Blood</i>. 2009;114(3):511-517. doi: 10.1182/blood-2009-03-212290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/19443659/pubmed" id="19443659" target="_blank">19443659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913201">
<a name="30913201"></a>American College of Obstetricians and Gynecologists (ACOG). Committee opinion no. 776: immune modulating therapies in pregnancy and lactation. <i>Obstet Gynecol</i>. 2019;133(4):e287-e295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/30913201/pubmed" id="30913201" target="_blank">30913201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20038753">
<a name="20038753"></a>Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. <i>Hypertension</i>. 2010;55(2):333-338. doi:10.1161/HYPERTENSIONAHA.109.143982<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/20038753/pubmed" id="20038753" target="_blank">20038753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35121075">
<a name="35121075"></a>Ao S, Gao X, Zhan J, et al. Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients. <i>J Am Acad Dermatol</i>. 2022;86(6):1236-1245. doi:10.1016/j.jaad.2022.01.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/35121075/pubmed" id="35121075" target="_blank">35121075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24458537">
<a name="24458537"></a>Arts EE, Fransen J, den Broeder AA, Popa CD, van Riel PL. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. <i>Ann Rheum Dis</i>. 2015;74(6):998-1003. doi:10.1136/annrheumdis-2013-204531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/24458537/pubmed" id="24458537" target="_blank">24458537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18467516">
<a name="18467516"></a>Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. <i>Ann Rheum Dis</i>. 2009;68(5):648-653. doi:10.1136/ard.2007.085852<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/18467516/pubmed" id="18467516" target="_blank">18467516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15829572">
<a name="15829572"></a>Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. <i>Ann Rheum Dis</i>. 2005;64(10):1421-1426. doi:10.1136/ard.2004.033993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/15829572/pubmed" id="15829572" target="_blank">15829572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30637218">
<a name="30637218"></a>Averbukh LD, Wu GY. Role of biologics in the development of autoimmune hepatitis: a review. <i>J Clin Transl Hepatol</i>. 2018;6(4):402-409. doi:10.14218/JCTH.2018.00039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/30637218/pubmed" id="30637218" target="_blank">30637218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29859201">
<a name="29859201"></a>Bae JM, Kwon HS, Kim GM, Park KS, Kim KJ. Paradoxical psoriasis following anti-TNF therapy in ankylosing spondylitis: a population-based cohort study. <i>J Allergy Clin Immunol</i>. 2018;142(3):1001-1003. doi:10.1016/j.jaci.2018.05.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/29859201/pubmed" id="29859201" target="_blank">29859201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11096165">
<a name="11096165"></a>Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. <i>N Engl J Med</i>. 2000;343(22):1586-1593.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/11096165/pubmed" id="11096165" target="_blank">11096165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22998733">
<a name="22998733"></a>Batycka-Baran A, Flaig M, Molin S, Ruzicka T, Prinz JC. Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment. <i>Expert Opin Drug Saf</i>. 2012;11(6):911-921. doi:10.1517/14740338.2012.727796<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/22998733/pubmed" id="22998733" target="_blank">22998733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25725941">
<a name="25725941"></a>Bavbek S, Ataman Ş, Akıncı A, Castells M. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. <i>J Allergy Clin Immunol Pract</i>. 2015;3(4):629-632. doi:10.1016/j.jaip.2015.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/25725941/pubmed" id="25725941" target="_blank">25725941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27836355">
<a name="27836355"></a>Behrendt P, Lüth S, Dammermann W, et al. Exacerbation of hepatitis E virus infection during anti-TNFα treatment. <i>Joint Bone Spine</i>. 2017;84(2):217-219. doi:10.1016/j.jbspin.2016.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/27836355/pubmed" id="27836355" target="_blank">27836355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18053024">
<a name="18053024"></a>Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF-alpha blocking agents with positive skin tests. <i>Allergy</i>. 2008;63(1):13813-9. doi:10.1111/j.1398-9995.2007.01536.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/18053024/pubmed" id="18053024" target="_blank">18053024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20581374">
<a name="20581374"></a>Berthelsen BG, Fjeldsøe-Nielsen H, Nielsen CT, Hellmuth E. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. <i>Rheumatology (Oxford)</i>. 2010;49(11):2225-2227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/20581374/pubmed" id="20581374" target="_blank">20581374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37001957">
<a name="37001957"></a>Bessone F, Björnsson ES. Drug-induced liver injury due to biologics and immune check point inhibitors. <i>Med Clin North Am</i>. 2023;107(3):623-640. doi:10.1016/j.mcna.2022.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/37001957/pubmed" id="37001957" target="_blank">37001957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21946459">
<a name="21946459"></a>Bilgen SA, Kilic L, Akdogan A, et al, "Effects of Anti-tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment," <i>J Clin Rheumatol</i>, 2011, 17(7):358-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/21946459/pubmed" id="21946459" target="_blank">21946459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25131534">
<a name="25131534"></a>Björnsson ES, Gunnarsson BI, Gröndal G, et al. <i>Risk of drug-induced liver injury from tumor necrosis factor antagonists</i>. <i>Clin Gastroenterol Hepatol</i>. 2015;13(3):602-608. doi:10.1016/j.cgh.2014.07.062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/25131534/pubmed" id="25131534" target="_blank">25131534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16705109">
<a name="16705109"></a>Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. <i>JAMA</i>. 2006;295(19):2275-2285. doi:10.1001/jama.295.19.2275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16705109/pubmed" id="16705109" target="_blank">16705109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17853314">
<a name="17853314"></a>Bovenschen HJ, Kop EN, Van De Kerkhof PC, Seyger MM. Etanercept-induced lichenoid reaction pattern in psoriasis. <i>J Dermatolog Treat</i>. 2006;17(6):381-383. doi:10.1080/09546630600967174<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/17853314/pubmed" id="17853314" target="_blank">17853314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9831171">
<a name="9831171"></a>Breedveld F, “New Tumor Necrosis Factor-Alpha Biologic Therapies for Rheumatoid Arthritis,” <i>Eur Cytokine Netw</i>, 1998, 9(3):233-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/9831171/pubmed" id="9831171" target="_blank">9831171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brenzys.1">
<a name="Brenzys.1"></a>Brenzys (etanercept) [product monograph]. Songdogyoyuk-ro, Yeonsu-gu, Incheon, Republic of Korea: Samsung Bioepis; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16937391">
<a name="16937391"></a>Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. <i>Am J Hematol</i>. 2007;82(1):45-52. doi: 10.1002/ajh.20752.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16937391/pubmed" id="16937391" target="_blank">16937391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15345498">
<a name="15345498"></a>Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. <i>Ann Rheum Dis</i>. 2004;63(12):1594-1600.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/15345498/pubmed" id="15345498" target="_blank">15345498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10881762">
<a name="10881762"></a>Centers for Disease Control and Prevention (CDC); American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. <i>MMWR Recomm Rep</i>. 2000;49(RR-6):1-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/10881762/pubmed" id="10881762" target="_blank">10881762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17910724">
<a name="17910724"></a>Charles CA, Leon A, Banta MR, Kirsner RS. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. <i>Int J Dermatol</i>. 2007;46(10):1095-1099.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/17910724/pubmed" id="17910724" target="_blank">17910724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34496051">
<a name="34496051"></a>Chen HK, Shao SC, Weng MY, Lin SJ, Hung MJ, Chan YY, Lai EC. Risk of heart failure in rheumatoid arthritis patients treated with tumor necrosis factor-α inhibitors. <i>Clin Pharmacol Ther</i>. 2021;110(6):1595-1603. doi:10.1002/cpt.2415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/34496051/pubmed" id="34496051" target="_blank">34496051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11889452">
<a name="11889452"></a>Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. <i>Transplantation</i>. 2002;73(4):665-667. doi: 10.1097/00007890-200202270-00035.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/11889452/pubmed" id="11889452" target="_blank">11889452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30412634">
<a name="30412634"></a>Choi JY, Chung JE, Park JH, Cho YS, Jung YW, Choi SA. Surveillance of adverse drug events associated with etanercept prescribed for juvenile idiopathic arthritis in a single center up to 9-years: a retrospective observational study. <i>PLoS One</i>. 2018;13(11):e0204573. doi:10.1371/journal.pone.0204573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/30412634/pubmed" id="30412634" target="_blank">30412634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33747126">
<a name="33747126"></a>Choi SJ, Ahn SM, Oh JS, et al. Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea.<i> Therap Adv Gastroenterol</i>. 2021;14:1756284821997794. doi:10.1177/1756284821997794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/33747126/pubmed" id="33747126" target="_blank">33747126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20667551">
<a name="20667551"></a>Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. <i>J Pediatr</i>. 2010;157(6):960-966.e1. doi:10.1016/j.jpeds.2010.06.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/20667551/pubmed" id="20667551" target="_blank">20667551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30289537">
<a name="30289537"></a>Conti F, Atzeni F, Massaro L, et al. The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. <i>Rheumatology (Oxford)</i>. 2018;57(57 Suppl 7):vii11-vii22. doi:10.1093/rheumatology/key209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/30289537/pubmed" id="30289537" target="_blank">30289537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24093840">
<a name="24093840"></a>Crowson CS, Liao KP, Davis JM 3rd, et. Rheumatoid arthritis and cardiovascular disease. <i>Am Heart J</i>. 2013;166(4):622-628.e1. doi:10.1016/j.ahj.2013.07.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/24093840/pubmed" id="24093840" target="_blank">24093840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34402108">
<a name="34402108"></a>Cyrenne BM, Parpia AS, Sibbald C. Paradoxical psoriasis in pediatric patients: a systematic review. <i>Pediatr Dermatol</i>. 2021;38(5):1086-1093. doi:10.1111/pde.14712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/34402108/pubmed" id="34402108" target="_blank">34402108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Immunex.1">
<a name="Immunex.1"></a>Data on file, Immunex Corporation.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14613288">
<a name="14613288"></a>Davis JC Jr, Van Der Heijde D, Braun J, et al; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. <i>Arthritis Rheum</i>. 2003;48(11):3230-3236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/14613288/pubmed" id="14613288" target="_blank">14613288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17310002">
<a name="17310002"></a>de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. <i>Arch Dermatol</i>. 2007;143(2):223-231. doi:10.1001/archderm.143.2.223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/17310002/pubmed" id="17310002" target="_blank">17310002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21369689">
<a name="21369689"></a>de Giorgi V, Benemei S, Grazzini M, Lotti T, Geppetti P. Rapid growth of Merkel cell carcinoma during etanercept treatment of psoriatic arthritis: cause or coincidence? <i>Acta Derm Venereol</i>. 2011;91(3):354-355. doi:10.2340/00015555-1038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/21369689/pubmed" id="21369689" target="_blank">21369689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16265699">
<a name="16265699"></a>Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. <i>J Rheumatol</i>. 2005;32(11):2183-2185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16265699/pubmed" id="16265699" target="_blank">16265699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24891317">
<a name="24891317"></a>Dougados M, van der Heijde D, Sieper J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis Rheumatol</i>. 2014;66(8):2091-2102. doi:10.1002/art.38721<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/24891317/pubmed" id="24891317" target="_blank">24891317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10843670">
<a name="10843670"></a>Eissner G, Kirchner S, Lindner H, et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. <i>J Immunol</i>. 2000;164(12):6193-6198. doi:10.4049/jimmunol.164.12.6193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/10843670/pubmed" id="10843670" target="_blank">10843670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20187135">
<a name="20187135"></a>Emery P, Breedveld F, van der Heijde D, et al. Combination of methotrexate and etanercept in early rheumatoid arthritis trial group. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. <i>Arthritis Rheum</i>. 2010;62(3):674-682. doi:10.1002/art.27268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/20187135/pubmed" id="20187135" target="_blank">20187135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Enbrel.1">
<a name="Enbrel.1"></a>Enbrel (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corporation; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Enbrel.2">
<a name="Enbrel.2"></a>Enbrel (etanercept) [product monograph]. Mississauga, Canada: Amgen Canada Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31921355">
<a name="31921355"></a>Engel S, Luessi F, Mueller A, Schopf RE, Zipp F, Bittner S. PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders. <i>Ther Adv Neurol Disord</i>. 2020;13:1756286419895155. doi:10.1177/1756286419895155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/31921355/pubmed" id="31921355" target="_blank">31921355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Erelzi.1">
<a name="Erelzi.1"></a>Erelzi (etanercept-szzs) [prescribing information]. Princeton, NJ: Sandoz Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Erelzi.2">
<a name="Erelzi.2"></a>Erelzi (etanercept) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18824922">
<a name="18824922"></a>Fathalla BM, Goldsmith DP, Pascasio JM, Baldridge A. Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept. <i>J Clin Rheumatol</i>. 2008;14(5):297-298. doi:10.1097/RHU.0b013e318188b1df<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/18824922/pubmed" id="18824922" target="_blank">18824922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26965410">
<a name="26965410"></a>Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. <i>J Am Acad Dermatol</i>. 2016;74(6):1153-1159. doi:10.1016/j.jaad.2016.01.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/26965410/pubmed" id="26965410" target="_blank">26965410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8717520">
<a name="8717520"></a>Feldmann M, Brennan FM, and Maini RN, “Role of Cytokines in Rheumatoid Arthritis,” <i>Annu Rev Immunol</i>, 1996, 14:397-440.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/8717520/pubmed" id="8717520" target="_blank">8717520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7779114">
<a name="7779114"></a>Felson DT, Anderson JJ, Boers M, et al, “American College of Rheumatology. Preliminary Definition of Improvement in Rheumatoid Arthritis,” <i>Arthritis Rheum</i>, 1995, 38(6):727-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/7779114/pubmed" id="7779114" target="_blank">7779114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25110258">
<a name="25110258"></a>Feuerstein JD, Cheifetz AS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). <i>Gastroenterol Clin North Am</i>. 2014;43(3):543-563. doi:10.1016/j.gtc.2014.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/25110258/pubmed" id="25110258" target="_blank">25110258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8637514">
<a name="8637514"></a>Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of Septic Shock With the Tumor Necrosis Factor Receptor:Fc Fusion Protein. The Soluble TNF Receptor Sepsis Study Group. <i>N Engl J Med. </i>1996;334(26):1697-1702.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/8637514/pubmed" id="8637514" target="_blank">8637514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25398933">
<a name="25398933"></a>Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. <i>Blood</i>. 2015;125(4):606-615. doi: 10.1182/blood-2014-08-551994.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/25398933/pubmed" id="25398933" target="_blank">25398933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34101387">
<a name="34101387"></a>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(7):924-939. doi:10.1002/acr.24596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/34101387/pubmed" id="34101387" target="_blank">34101387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26692395">
<a name="26692395"></a>French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-α agents. <i>Drug Saf</i>. 2016;39(3):199-208. doi:10.1007/s40264-015-0366-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/26692395/pubmed" id="26692395" target="_blank">26692395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12115173">
<a name="12115173"></a>Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. <i>Arthritis Rheum</i>. 2002;46(6):1443-1450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/12115173/pubmed" id="12115173" target="_blank">12115173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23333219">
<a name="23333219"></a>Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. <i>Clin Gastroenterol Hepatol</i>. 2013;11(5):558-564.e3. doi:10.1016/j.cgh.2012.12.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/23333219/pubmed" id="23333219" target="_blank">23333219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31731980">
<a name="31731980"></a>Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond. <i>Clin Chest Med</i>. 2019;40(4):721-739. doi:10.1016/j.ccm.2019.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/31731980/pubmed" id="31731980" target="_blank">31731980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31855274">
<a name="31855274"></a>Gomes N, Leão B, Abreu C, Azevedo F, Magina S. Asymptomatic reactivation of hepatitis B virus after prolonged treatment with etanercept. <i>Acta Dermatovenerol Alp Pannonica Adriat</i>. 2019 Dec;28(4):183-184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/31855274/pubmed" id="31855274" target="_blank">31855274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35718887">
<a name="35718887"></a>Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(9):1399-1408. doi:10.1002/acr.24893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/35718887/pubmed" id="35718887" target="_blank">35718887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22056398">
<a name="22056398"></a>Grijalva CG, Chen L, Delzell et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. <i>JAMA</i>. 2011;306(21):2331-2339. doi:10.1001/jama.2011.1692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/22056398/pubmed" id="22056398" target="_blank">22056398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31240749">
<a name="31240749"></a>Groth D, Perez M, Treat JR, et al. Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients. <i>Pediatr Dermatol</i>. 2019;36(5):613-617. doi:10.1111/pde.13859<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/31240749/pubmed" id="31240749" target="_blank">31240749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16981296">
<a name="16981296"></a>Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>J Rheumatol</i>. 2006;33(11):2167-2172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16981296/pubmed" id="16981296" target="_blank">16981296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30006049">
<a name="30006049"></a>Hansel K, Bianchi L, Tramontana M, et al. Immediate local and systemic hypersensitivity due to etanercept and adalimumab. <i>J Allergy Clin Immunol Pract</i>. 2019;7(2):726-727. doi:10.1016/j.jaip.2018.06.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/30006049/pubmed" id="30006049" target="_blank">30006049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23383700">
<a name="23383700"></a>Hanson RL, Gannon MJ, Khamo N, Sodhi M, Orr AM, Stubbings J. Improvement in safety monitoring of biologic response modifiers after the implementation of clinical care guidelines by a specialty. <i>J Manag Care Pharm</i>. 2013;19(1):49-67. doi:10.18553/jmcp.2013.19.1.49<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/23383700/pubmed" id="23383700" target="_blank">23383700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18563514">
<a name="18563514"></a>Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. <i>Clin Rheumatol</i>. 2008;27(8):1063-1066. doi:10.1007/s10067-008-0885-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/18563514/pubmed" id="18563514" target="_blank">18563514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28737221">
<a name="28737221"></a>Havmose M, Thomsen SF. Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases. <i>Int J Dermatol</i>. 2017;56(11):1087-1102. doi:10.1111/ijd.13691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/28737221/pubmed" id="28737221" target="_blank">28737221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22515220">
<a name="22515220"></a>Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. <i>J Cutan Pathol</i>. 2012;39(5):481-492. doi:10.1111/j.1600-0560.2012.01894.x. PMID: 22515220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/22515220/pubmed" id="22515220" target="_blank">22515220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26768759">
<a name="26768759"></a>Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. <i>J Allergy Clin Immunol</i>. 2016;137(1):19-27. doi:10.1016/j.jaci.2015.10.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/26768759/pubmed" id="26768759" target="_blank">26768759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9345421">
<a name="9345421"></a>Hohlfeld R. Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? <i>Mult Scler</i>. 1996;1(6):376-378. doi:10.1177/135245859600100619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/9345421/pubmed" id="9345421" target="_blank">9345421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35694729">
<a name="35694729"></a>Husein-ElAhmed H, Steinhoff M. Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review. <i>J Dermatolog Treat</i>. 2022;33(7):2886-2893. doi:10.1080/09546634.2022.2089331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/35694729/pubmed" id="35694729" target="_blank">35694729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33945946">
<a name="33945946"></a>Hutto SK, Rice DR, Mateen FJ. CNS demyelination with TNFα inhibitor exposure:aA retrospective cohort study. <i>J Neuroimmunol</i>. 2021;356:577587. doi: 0.1016/j.jneuroim.2021.577587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/33945946/pubmed" id="33945946" target="_blank">33945946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16837489">
<a name="16837489"></a>Iannone F, Trotta F, Montecucco et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. <i>Ann Rheum Dis</i>. 2007;66(2):249-252. doi:10.1136/ard.2006.058776<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16837489/pubmed" id="16837489" target="_blank">16837489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35274741">
<a name="35274741"></a>Jacobsen A, Olabi B, Langley A, et al. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. <i>Cochrane Database Syst Rev</i>. 2022;3(3):CD013130. doi:10.1002/14651858.CD013130.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/35274741/pubmed" id="35274741" target="_blank">35274741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23557269">
<a name="23557269"></a>Juhász K, Buzás K, Duda E. Importance of reverse signaling of the TNF superfamily in immune regulation. <i>Expert Rev Clin Immunol</i>. 2013;9(4):335-348. doi:10.1586/eci.13.14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/23557269/pubmed" id="23557269" target="_blank">23557269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31845616">
<a name="31845616"></a>Kalinowska-Lyszczarz A, Fereidan-Esfahani M, Guo Y, Lucchinetti CF, Tobin WO. Pathological findings in central nervous system demyelination associated with infliximab. <i>Mult Scler</i>. 2020;26(9):1124-1129. doi:10.1177/1352458519894710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/31845616/pubmed" id="31845616" target="_blank">31845616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20595298">
<a name="20595298"></a>Keeling S, Wolbink GJ. Measuring multiple etanercept levels in the breast milk of a nursing mother with rheumatoid arthritis. <i>J Rheumatol</i>. 2010;37(7):1551.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/20595298/pubmed" id="20595298" target="_blank">20595298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28337644">
<a name="28337644"></a>Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. <i>Curr Neurol Neurosci Rep</i>. 2017;17(4):36. doi:10.1007/s11910-017-0742-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/28337644/pubmed" id="28337644" target="_blank">28337644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16699531">
<a name="16699531"></a>Kennedy GA, Butler J, Western R, Morton J, Durrant S, Hill GR. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. <i>Bone Marrow Transplant</i>. 2006;37(12):1143-1147. doi: 10.1038/sj.bmt.1705380.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16699531/pubmed" id="16699531" target="_blank">16699531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20472597">
<a name="20472597"></a>Klarenbeek NB, van der Kooij SM, Huizinga TJ, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. <i>Ann Rheum Dis</i>. 2010;69(7):1342-1345. doi:10.1136/ard.2009.124180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/20472597/pubmed" id="20472597" target="_blank">20472597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34903405">
<a name="34903405"></a>Krajewski A, Maciejewska-Markiewicz D, Jakubczyk K, et al. Impact of multiple medical interventions on mortality, length of hospital stay and reepithelialization time in toxic epidermal necrolysis, Steven-Johnsons syndrome, and TEN/SJS overlap - metanalysis and metaregression of observational studies. <i>Burns</i>. 2022;48(2):263-280. doi:10.1016/j.burns.2021.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/34903405/pubmed" id="34903405" target="_blank">34903405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29564668">
<a name="29564668"></a>Kok B, Lester ELW, Lee WM, et al. Acute liver failure from tumor necrosis factor-α antagonists: report of four cases and literature review. <i>Dig Dis Sci</i>. 2018;63(6):1654-1666. doi:10.1007/s10620-018-5023-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/29564668/pubmed" id="29564668" target="_blank">29564668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29895751">
<a name="29895751"></a>Kotyla PJ. Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid Arthritis and Heart Failure? Int J Mol Sci. 2018 Jun 12;19(6):1739. doi: 10.3390/ijms19061739. PMID: 29895751; PMCID: PMC6032136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/29895751/pubmed" id="29895751" target="_blank">29895751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30767720">
<a name="30767720"></a>Kumar N, Abboud H. Iatrogenic CNS demyelination in the era of modern biologics. <i>Mult Scler</i>. 2019;25(8):1079-1085. doi:10.1177/1352458519828601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/30767720/pubmed" id="30767720" target="_blank">30767720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12755552">
<a name="12755552"></a>Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. <i>Ann Intern Med</i>. 2003;138(10):807-811. doi:10.7326/0003-4819-138-10-200305200-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/12755552/pubmed" id="12755552" target="_blank">12755552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32421186">
<a name="32421186"></a>Kunchok A, Aksamit AJ Jr, Davis JM 3rd, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. <i>JAMA Neurol</i>. 2020;77(8):937-946. doi:10.1001/jamaneurol.2020.1162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/32421186/pubmed" id="32421186" target="_blank">32421186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36412234">
<a name="36412234"></a>Kurokami Y, Ueda-Hayakawa I, Fujimoto M. Etanercept-induced erythema nodosum in a patient with rheumatoid arthritis: case report and literature review. <i>J Dermatol</i>. 2023;50(3):e108-e109. doi:10.1111/1346-8138.16636<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/36412234/pubmed" id="36412234" target="_blank">36412234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21719446">
<a name="21719446"></a>Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. <i>Ann Rheum Dis</i>. 2011;70(10):1719-1725. doi: 0.1136/ard.2010.148783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/21719446/pubmed" id="21719446" target="_blank">21719446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34427860">
<a name="34427860"></a>Lau G, Yu ML, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. <i>Hepatol Int</i>. 2021;15(5):1031-1048. doi10.1007/s12072-021-10239-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/34427860/pubmed" id="34427860" target="_blank">34427860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17300238">
<a name="17300238"></a>Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. <i>Br J Dermatol</i>. 2007;156(3):486-91. doi:10.1111/j.1365-2133.2007.07682.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/17300238/pubmed" id="17300238" target="_blank">17300238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18753157">
<a name="18753157"></a>Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. <i>Ann Rheum Dis</i>. 2009 Jul;68(7):1136-1145. doi:10.1136/ard.2008.091025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/18753157/pubmed" id="18753157" target="_blank">18753157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18042798">
<a name="18042798"></a>Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. <i>Blood.</i> 2008;111(4):2470-2475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/18042798/pubmed" id="18042798" target="_blank">18042798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. <i>Am J Gastroenterol</i>. 2018;113(4):481-517. doi:10.1038/ajg.2018.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29611085">
<a name="29611085"></a>Li C, Wu X, Cao Y, et al. Paradoxical skin lesions induced by anti-TNF-α agents in SAPHO syndrome. <i>Clin Rheumatol</i>. 2019a;38(1):53-61. doi:10.1007/s10067-018-4083-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/29611085/pubmed" id="29611085" target="_blank">29611085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31093599">
<a name="31093599"></a>Li SJ, Perez-Chada LM, Merola JF. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. <i>J Psoriasis Psoriatic Arthritis</i>. 2019b;4(2):70-80. doi:10.1177/2475530318810851<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/31093599/pubmed" id="31093599" target="_blank">31093599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28219691">
<a name="28219691"></a>Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. <i>Gastroenterology</i>. 2017 May;152(6):1297-1309. doi:10.1053/j.gastro.2017.02.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/28219691/pubmed" id="28219691" target="_blank">28219691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22948700">
<a name="22948700"></a>Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, “Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,” <i>JAMA</i>, 2012, 308(9): 898-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/22948700/pubmed" id="22948700" target="_blank">22948700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16732547">
<a name="16732547"></a>Lovell DJ, Reiff A, Jones OY, et al; Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. <i>Arthritis Rheum</i>. 2006;54(6):1987-1994. doi:10.1002/art.21885<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16732547/pubmed" id="16732547" target="_blank">16732547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26269397">
<a name="26269397"></a>Maksymowych WP, Dougados M, van der Heijde D, et al. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study.<i> Ann Rheum Dis</i>. 2016;75(7):1328-1335. doi:10.1136/annrheumdis-2015-207596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/26269397/pubmed" id="26269397" target="_blank">26269397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32202630">
<a name="32202630"></a>Martin PJ. How I treat steroid-refractory acute graft-versus-host disease. <i>Blood</i>. 2020;135(19):1630-1638. doi:10.1182/blood.2019000960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/32202630/pubmed" id="32202630" target="_blank">32202630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22510384">
<a name="22510384"></a>Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. <i>Biol Blood Marrow Transplant</i>. 2012;18(8):1150-1163. doi:10.1016/j.bbmt.2012.04.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/22510384/pubmed" id="22510384" target="_blank">22510384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19505409">
<a name="19505409"></a>Massarotti M, Marasini B. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol. 2009;22(2):547-549. doi:10.1177/039463200902200234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/19505409/pubmed" id="19505409" target="_blank">19505409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28260984">
<a name="28260984"></a>Matsui T, Umetsu R, Kato Y, et al. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. <i>Int J Med Sci</i>. 2017;14(2):102-109. doi:10.7150/ijms.17025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/28260984/pubmed" id="28260984" target="_blank">28260984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28356445">
<a name="28356445"></a>McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/28356445/pubmed" id="28356445" target="_blank">28356445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10972371">
<a name="10972371"></a>Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. <i>Lancet.</i> 2000;356(9227):385-390.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/10972371/pubmed" id="10972371" target="_blank">10972371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16463435">
<a name="16463435"></a>Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. <i>J Rheumatol</i>. 2006;33(4):712-721.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16463435/pubmed" id="16463435" target="_blank">16463435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15248226">
<a name="15248226"></a>Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. <i>Arthritis Rheum</i>. 2004;50(7):2264-2272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/15248226/pubmed" id="15248226" target="_blank">15248226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30772098">
<a name="30772098"></a>Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>J Am Acad Dermatol</i>. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/30772098/pubmed" id="30772098" target="_blank">30772098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24685910">
<a name="24685910"></a>Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.<i> Ann Rheum Dis</i>. 2015;74(6):1087-1093. doi:10.1136/annrheumdis-2013-204851<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/24685910/pubmed" id="24685910" target="_blank">24685910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11762947">
<a name="11762947"></a>Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. <i>Arthritis Rheum</i>. 2001;44(12):2862-2869. doi:10.1002/1529-0131(200112)44:12&lt;2862::aid-art474&gt;3.0.co;2-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/11762947/pubmed" id="11762947" target="_blank">11762947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18433400">
<a name="18433400"></a>Montiel PM, Solis JA, Chirinos JA, a Casis B, Sánchez F, Rodríguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. <i>Liver Int</i>. 2008;28(5):718-720. doi:10.1111/j.1478-3231.2007.01665.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/18433400/pubmed" id="18433400" target="_blank">18433400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34625145">
<a name="34625145"></a>Montolio Chiva L, Martínez Ferrer À, Mateu Puchades A, Campos Fernández C, Narváez Garcia J, Alegre Sancho JJ. Psoriasis induced by biological therapy. <i>Reumatol Clin (Engl Ed)</i>. 2021;17(8):437-439. doi:10.1016/j.reumae.2020.06.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/34625145/pubmed" id="34625145" target="_blank">34625145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9219699">
<a name="9219699"></a>Moreland LW, Baumgartner SW, Schiff MH, et al, “Treatment of Rheumatoid Arthritis With a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein,” <i>N Engl J Med</i>, 1997, 337(3):141-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/9219699/pubmed" id="9219699" target="_blank">9219699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19822717">
<a name="19822717"></a>Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. <i>Ann Rheum Dis</i>. 2009;68(11):1793-1794.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/19822717/pubmed" id="19822717" target="_blank">19822717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23330811">
<a name="23330811"></a>Murdaca G, Spanò F, Puppo F. Selective TNF-α inhibitor-induced injection site reactions. <i>Expert Opin Drug Saf</i>. 2013;12(2):187-193. doi:10.1517/14740338.2013.755957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/23330811/pubmed" id="23330811" target="_blank">23330811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21216812">
<a name="21216812"></a>Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. <i>Ann Rheum Dis</i>. 2011;70(3):482-487. doi:10.1136/ard.2010.135871<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/21216812/pubmed" id="21216812" target="_blank">21216812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33349983">
<a name="33349983"></a>Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris - part 1: treatment and monitoring recommendations. <i>J Eur Acad Dermatol Venereol.</i> 2020;34(11):2461-2498. doi:10.1111/jdv.16915<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/33349983/pubmed" id="33349983" target="_blank">33349983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25609412">
<a name="25609412"></a>Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. <i>Ann Rheum Dis</i>. 2016;75(2):341-347. doi:10.1136/annrheumdis-2013-204987<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/25609412/pubmed" id="25609412" target="_blank">25609412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9844625">
<a name="9844625"></a>“New Drugs for Rheumatoid Arthritis,” <i>Med Lett Drugs Ther</i>, 1998, 40(1040):110-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/9844625/pubmed" id="9844625" target="_blank">9844625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15692992">
<a name="15692992"></a>Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. <i>Arthritis Rheum</i>. 2005;52(2):412-420. doi:10.1002/art.20855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/15692992/pubmed" id="15692992" target="_blank">15692992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33393825">
<a name="33393825"></a>Olteanu C, Shear NH, Burnett M, et al. Retrospective study of patients with SJS/TEN treated at a tertiary burn unit in Canada: overview of 17 years of treatment. <i>J Cutan Med Surg</i>. 2021;25(3):271-280. doi:10.1177/1203475420982550<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/33393825/pubmed" id="33393825" target="_blank">33393825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15124283">
<a name="15124283"></a>Ostensen M, Eigenmann GO. Etanercept in breast milk. <i>J Rheumatol</i>. 2004;31(5):1017-1018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/15124283/pubmed" id="15124283" target="_blank">15124283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21159830">
<a name="21159830"></a>Özen S, Bilginer Y, Aktay Ayaz N, et al, "Anti-interleukin 1 Treatment for Patients With Familial Mediterranean Fever Resistant to Colchicine," <i>J Rheumatol</i>, 2011, 38(3):516-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/21159830/pubmed" id="21159830" target="_blank">21159830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20605256">
<a name="20605256"></a>Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. <i>J Am Acad Dermatol</i>. 2010;63(5):762-768. doi:10.1016/j.jaad.2010.04.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/20605256/pubmed" id="20605256" target="_blank">20605256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18199863">
<a name="18199863"></a>Paller AS, Siegfried EC, Langley RG, et al; Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. <i>N Engl J Med</i>. 2008;358(3):241-251. doi:10.1056/NEJMoa066886<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/18199863/pubmed" id="18199863" target="_blank">18199863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26775775">
<a name="26775775"></a>Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. <i>J Am Acad Dermatol</i>. 2016;74(2):280-287.e1-e3. doi: 10.1016/j.jaad.2015.09.056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/26775775/pubmed" id="26775775" target="_blank">26775775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24928706">
<a name="24928706"></a>Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. <i>J Am Acad Dermatol</i>. 2014;71(2):278-283. doi:10.1016/j.jaad.2014.04.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/24928706/pubmed" id="24928706" target="_blank">24928706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33021477">
<a name="33021477"></a>Paradisi A, Abeni D, Didona D, Ricci F, Canzona F, Didona B. A new case series on etanercept treatment for toxic epidermal necrolysis. <i>Eur J Dermatol</i>. 2020;30(5):561-568. doi:10.1684/ejd.2020.3883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/33021477/pubmed" id="33021477" target="_blank">33021477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21941193">
<a name="21941193"></a>Parakkal D, Sifuentes H, Semer R, et al, “Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-α Inhibitor Therapy: Expanding the Groups at Risk,” <i>Eur J Gastroenterol Hepatol</i>, 2011, 23(12):1150-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/21941193/pubmed" id="21941193" target="_blank">21941193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32357984">
<a name="32357984"></a>Pasadyn SR, Knabel D, Fernandez AP, Warren CB. Cutaneous adverse effects of biologic medications. <i>Cleve Clin J Med</i>. 2020;87(5):288-299. doi:10.3949/ccjm.87a.19119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/32357984/pubmed" id="32357984" target="_blank">32357984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28854831">
<a name="28854831"></a>Pérez-De-Lis M, Retamozo S, Flores-Chávez A, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). <i>Expert Opin Drug Saf</i>. 2017;16(11):1255-1271. doi:10.1080/14740338.2017.1372421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/28854831/pubmed" id="28854831" target="_blank">28854831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31466921">
<a name="31466921"></a>Pham CH, Gillenwater TJ, Nagengast E, McCullough MC, Peng DH, Garner WL. Combination therapy: etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Burns</i>. 2019;45(7):1634-1638. doi:10.1016/j.burns.2018.12.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/31466921/pubmed" id="31466921" target="_blank">31466921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28110056">
<a name="28110056"></a>Picard M, Galvão VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):600-609. doi: 10.1016/j.jaip.2016.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/28110056/pubmed" id="28110056" target="_blank">28110056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28468732">
<a name="28468732"></a>Pinheiro RR, Lencastre A. Henoch-Schönlein purpura during anti-TNFα therapy: a fortuitous event or an indication to stop therapy? <i>Eur J Dermatol</i>. 2017;27(3):304-305. doi:10.1684/ejd.2017.2979<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/28468732/pubmed" id="28468732" target="_blank">28468732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31048415">
<a name="31048415"></a>Portman MA, Dahdah NS, Slee A, et al. Etanercept with IVIg for acute Kawasaki disease: a randomized controlled trial. <i>Pediatrics</i>. 2019;143(6):e20183675.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/31048415/pubmed" id="31048415" target="_blank">31048415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21392603">
<a name="21392603"></a>Portman MA, Olson A, Soriano B, Dahdah N, Williams R, Kirkpatrick E. Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. <i>Am Heart J</i>. 2011;161(3):494-499. doi:10.1016/j.ahj.2010.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/21392603/pubmed" id="21392603" target="_blank">21392603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22289732">
<a name="22289732"></a>Puxeddu I, Giori L, Rocchi V, Bazzichi L, Bombardieri S, Tavoni A, Migliorini P, Del Corso I. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. <i>Ann Allergy Asthma Immunol</i>. 2012;108(2):123-124. doi:10.1016/j.anai.2011.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/22289732/pubmed" id="22289732" target="_blank">22289732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25107559">
<a name="25107559"></a>Raaschou P, Frisell T, Askling J; ARTIS Study Group. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. <i>Ann Rheum Dis</i>. 2015;74(12):2137-2143. doi:10.1136/annrheumdis-2014-205745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/25107559/pubmed" id="25107559" target="_blank">25107559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28543445">
<a name="28543445"></a>Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. <i>Australas J Dermatol</i>. 2018;59(2):86-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/28543445/pubmed" id="28543445" target="_blank">28543445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ramey.1">
<a name="Ramey.1"></a>Ramey DR, Fries JF, and Singh G, “The Health Assessment Questionnaire 1995 - Status and Review,” Spilker B, ed, <i>Quality of Life and Pharmacoeconomics in Clinical Trials</i>, 2nd ed, Philadelphia, PA: Lippincott-Raven, 1996.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17632266">
<a name="17632266"></a>Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. <i>Medicine (Baltimore)</i>. 2007;86(4):242-251. doi:10.1097/MD.0b013e3181441a68<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/17632266/pubmed" id="17632266" target="_blank">17632266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19854301">
<a name="19854301"></a>Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? <i>Autoimmun Rev</i>. 2010;9(3):188-193. doi:10.1016/j.autrev.2009.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/19854301/pubmed" id="19854301" target="_blank">19854301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16488326">
<a name="16488326"></a>Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. <i>J Am Acad Dermatol</i>. 2006;54(3)(suppl 2):S128-S134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16488326/pubmed" id="16488326" target="_blank">16488326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15767026">
<a name="15767026"></a>Rubin RL. Drug-induced lupus. <i>Toxicology</i>. 2005;209(2):135-147. doi:10.1016/j.tox.2004.12.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/15767026/pubmed" id="15767026" target="_blank">15767026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32944048">
<a name="32944048"></a>Sadeghian D, Azmoudeh-Ardalan F, Dashti-Khavidaki S, Fakhar N. Orthotopic liver transplantation for etanercept-induced acute hepatic failure: a case report. <i>Iran J Pathol</i>. 2020;15(4):338-341. doi:10.30699/ijp.2020.117000.2269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/32944048/pubmed" id="32944048" target="_blank">32944048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16956436">
<a name="16956436"></a>Sakallioglu O, Duzova A, and Özen S, "Enercept in the Treatment of Arthritis in a Patient With Familial Mediterranean Fever," <i>Clin Exp Rheumatol</i>, 2006, 24(4):435-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16956436/pubmed" id="16956436" target="_blank">16956436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29593717">
<a name="29593717"></a>Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor necrosis factor α and regulatory T cells in oncoimmunology. <i>Front Immunol</i>. 2018;9:444. doi:10.3389/fimmu.2018.00444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/29593717/pubmed" id="29593717" target="_blank">29593717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32135533">
<a name="32135533"></a>Salvador-Rodriguez L, Montero-Vílchez T, Arias-Santiago S, Molina-Leyva A. Paradoxical hidradenitis suppurativa in patients receiving TNF-α inhibitors: case series, systematic review, and case meta-analysis. <i>Dermatology</i>. 2020;236(4):307-313. doi:10.1159/000506074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/32135533/pubmed" id="32135533" target="_blank">32135533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21470384">
<a name="21470384"></a>Sassa Y, Kawano Y, Yamana T, Mashima T, Ishibashi T. A change in treatment from etanercept to infliximab was effective to control scleritis in a patient with rheumatoid arthritis.<i> Acta Ophthalmol</i>. 2012;90(2):e161-162. doi:10.1111/j.1755-3768.2010.02090.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/21470384/pubmed" id="21470384" target="_blank">21470384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3136775">
<a name="3136775"></a>Saxne T, Palladino MA Jr, Heinegard D, et al, “Detection of Tumor Necrosis Factor Alpha but Not Tumor Necrosis Factor Beta in Rheumatoid Arthritis Synovial Fluid and Serum,” <i>Arthritis Rheum</i>, 1988, 31(8):1041-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/3136775/pubmed" id="3136775" target="_blank">3136775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16439435">
<a name="16439435"></a>Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. <i>Ann Rheum Dis</i>. 2006;65(7):889-894. doi:10.1136/ard.2005.043166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16439435/pubmed" id="16439435" target="_blank">16439435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25169849">
<a name="25169849"></a>Sedger LM, McDermott MF. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. <i>Cytokine Growth Factor Rev</i>. 2014;25(4):453-472. doi:10.1016/j.cytogfr.2014.07.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/25169849/pubmed" id="25169849" target="_blank">25169849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19371261">
<a name="19371261"></a>Sendur OF, Turan Y, Berkit IK, Tastaban E. Angio-oedema in a patient treated with etanercept for rheumatoid arthritis. <i>Basic Clin Pharmacol Toxicol</i>. 2009;104(6):488-490. doi: 10.1111/j.1742-7843.2009.00401.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/19371261/pubmed" id="19371261" target="_blank">19371261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23287362">
<a name="23287362"></a>Seror R, Richez C, Sordet C, et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. <i>Rheumatology (Oxford)</i>. 2013;52(5):868-874. doi: 10.1093/rheumatology/kes375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/23287362/pubmed" id="23287362" target="_blank">23287362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32025603">
<a name="32025603"></a>Shah P, Sundaram V, Björnsson E. Biologic and checkpoint Inhibitor-Induced liver injury: a systematic literature review. <i>Hepatol Commun</i>. 2020;4(2):172-184. doi:10.1002/hep4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/32025603/pubmed" id="32025603" target="_blank">32025603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11867114">
<a name="11867114"></a>Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. <i>Lancet</i>. 2002;359(9306):579-580. doi:10.1016/S0140-6736(02)07714-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/11867114/pubmed" id="11867114" target="_blank">11867114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21752492">
<a name="21752492"></a>Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. <i>J Am Acad Dermatol</i>. 2012;67(5):e179-e185. doi:10.1016/j.jaad.2011.05.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/21752492/pubmed" id="21752492" target="_blank">21752492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20833444">
<a name="20833444"></a>Siegfried EC, Eichenfield LF, Paller AS, Pariser D, Creamer K, Kricorian G. Intermittent etanercept therapy in pediatric patients with psoriasis. <i>J Am Acad Dermatol</i>. 2010;63(5):769-774. doi:10.1016/j.jaad.2009.10.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/20833444/pubmed" id="20833444" target="_blank">20833444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22473917">
<a name="22473917"></a>Singh JA, Furst DE, Bharat A, et al, “2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,” <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(5):625-639.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/22473917/pubmed" id="22473917" target="_blank">22473917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21328309">
<a name="21328309"></a>Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2011(2):CD008794. doi:10.1002/14651858.CD008794.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/21328309/pubmed" id="21328309" target="_blank">21328309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30876964">
<a name="30876964"></a>Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2020;18(1):69-81.e3. doi:10.1016/j.cgh.2019.02.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/30876964/pubmed" id="30876964" target="_blank">30876964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8137429">
<a name="8137429"></a>Smith CA, Farrah T, and Goodwin RG, “The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death,” <i>Cell</i>, 1994, 76(6):959-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/8137429/pubmed" id="8137429" target="_blank">8137429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25776112">
<a name="25776112"></a>Solomon DH, Reed GW, Kremer Jm, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. <i>Arthritis Rheumatol</i>. 2015;67(6):1449-1455. doi:10.1002/art.39098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/25776112/pubmed" id="25776112" target="_blank">25776112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23322405">
<a name="23322405"></a>Soriano A, Verecchia E, Afeltra A, et al, "IL-1β Biological Treatment of Familial Mediterranean Fever," <i>Clin Rev Allergy Immunol</i>, 2013, Jan 16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/23322405/pubmed" id="23322405" target="_blank">23322405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21791449">
<a name="21791449"></a>Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? <i>Ann Rheum Dis</i>. 2011;70(11):1914-1920. doi:10.1136/ard.2011.151043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/21791449/pubmed" id="21791449" target="_blank">21791449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20064207">
<a name="20064207"></a>Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.<i> Arthritis Res Ther</i>. 2010;12(1):R5. doi:10.1186/ar2904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/20064207/pubmed" id="20064207" target="_blank">20064207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33863839">
<a name="33863839"></a>Taylor T, Galloway J, Davies R, Hyrich K, Dobson, R. Demyelinating events following initiation of anti-TNFα therapy in the British Society for Rheumatology Biologics Registry in rheumatoid arthritis. <i>Neurol Neuroimmunol Neuroinflamm. </i>2021;8:e992. doi10.1212/NXI.0000000000000992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/33863839/pubmed" id="33863839" target="_blank">33863839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29405329">
<a name="29405329"></a>Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <i>Hepatology</i>. 2018;67(4):1560-1599. doi:10.1002/hep.29800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/29405329/pubmed" id="29405329" target="_blank">29405329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35598882">
<a name="35598882"></a>Tian CC, Ai XC, Ma JC, et al. Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Ann Allergy Asthma Immunol</i>. 2022;129(3):360-365.e1. doi:10.1016/j.anai.2022.05.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/35598882/pubmed" id="35598882" target="_blank">35598882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22662786">
<a name="22662786"></a>Titos Arcos JC, Hallal H, Robles M, Andrade RJ. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. <i>Rev Esp Enferm Dig</i>. 2012;104(5):282-284. doi:10.4321/s1130-01082012000500014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/22662786/pubmed" id="22662786" target="_blank">22662786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22941219">
<a name="22941219"></a>van Denderen JC, Blom GJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept. <i>Clin Rheumatol</i>. 2012;31(12):1677-1682. doi:10.1007/s10067-012-2072-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/22941219/pubmed" id="22941219" target="_blank">22941219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16968715">
<a name="16968715"></a>van der Heijde D, Da Silva JC, Dougados M, et al; Etanercept Study 314 Investigators. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. <i>Ann Rheum Dis</i>. 2006;65(12):1572-1577. doi:10.1136/ard.2006.056747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16968715/pubmed" id="16968715" target="_blank">16968715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21459936">
<a name="21459936"></a>van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. <i>J Rheumatol</i>. 2011;38(7):1441-1446. doi:10.3899/jrheum.100809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/21459936/pubmed" id="21459936" target="_blank">21459936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8960740">
<a name="8960740"></a>van Oosten BW, Barkhof F, Truyen L, et al, “Increased MRI Activity and Immune Activation in Two Multiple Sclerosis Patients Treated With the Monoclonal Anti-tumor Necrosis Factor Antibody cA2,” <i>Neurology</i>, 1996, 47(6):1531-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/8960740/pubmed" id="8960740" target="_blank">8960740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yu.1">
<a name="Yu.1"></a>van Tubergen A. Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12851868">
<a name="12851868"></a>Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. <i>Gastroenterology</i>. 2003;125(1):32-39. doi:10.1016/s0016-5085(03)00701-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/12851868/pubmed" id="12851868" target="_blank">12851868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9826720">
<a name="9826720"></a>Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. <i>Proc Natl Acad Sci U S A</i>. 1998;95(24):14447-14452. doi: 10.1073/pnas.95.24.14447<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/9826720/pubmed" id="9826720" target="_blank">9826720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29400697">
<a name="29400697"></a>Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. <i>J Clin Invest</i>. 2018;128(3):985-996. doi:10.1172/JCI93349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/29400697/pubmed" id="29400697" target="_blank">29400697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31436026">
<a name="31436026"></a>Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. <i>Arthritis Care</i>
<i>Res (Hoboken)</i>. 2019;71(10):1285-1299. doi:10.1002/acr.24025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/31436026/pubmed" id="31436026" target="_blank">31436026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9920948">
<a name="9920948"></a>Weinblatt ME, Kremer JM, Bankhurst AD, et al, “A Trial of Etanercept, A Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients With Rheumatoid Arthritis Receiving Methotrexate,” <i>N Engl J Med</i>, 1999, 340(4):253-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/9920948/pubmed" id="9920948" target="_blank">9920948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16490850">
<a name="16490850"></a>Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitislike reaction to subcutaneous etanercept injection.<i> Arch Dermatol</i>. 2006;142(2):218-220. doi:10.1001/archderm.142.2.218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16490850/pubmed" id="16490850" target="_blank">16490850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16447241">
<a name="16447241"></a>Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. <i>Arthritis Rheum</i>. 2006;54(2):628-634. doi:10.1002/art.21568<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/16447241/pubmed" id="16447241" target="_blank">16447241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20685255">
<a name="20685255"></a>Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. <i>Biol Blood Marrow Transplant</i>. 2011;17(1):1-17. doi: 10.1016/j.bbmt.2010.05.011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/20685255/pubmed" id="20685255" target="_blank">20685255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8245488">
<a name="8245488"></a>Wooley PH, Dutcher J, Widmer MB, et al, “Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice,” <i>J Immunol</i>, 1993, 151(11):6602-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/8245488/pubmed" id="8245488" target="_blank">8245488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24185311">
<a name="24185311"></a>Yanai H, Shuster D, Calabrese E, Mlynarsky L, Tumuluri S, Cohen RD. The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. <i>Inflamm Bowel Dis</i>. 2013;19(13):2778-2786. doi:10.1097/01.MIB.0000435435.91988.b6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/24185311/pubmed" id="24185311" target="_blank">24185311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15703360">
<a name="15703360"></a>Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. <i>J Clin Pharmacol</i>. 2005;45(3):246-256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/15703360/pubmed" id="15703360" target="_blank">15703360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35131514">
<a name="35131514"></a>Zhang J, Lu CW, Chen CB, et al. Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study. <i>J Allergy Clin Immunol Pract</i>. 2022;10(5):1295-1304.e6. doi:10.1016/j.jaip.2022.01.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information/abstract-text/35131514/pubmed" id="35131514" target="_blank">35131514</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8925 Version 340.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
